

TAYSIDE PRESCRIBER

Tayside DTC Supplement No 78

April 2008

Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

SMC Advice issued in April 2008

Medicine	Indication	Local recommendation category	Comments and useful links
Efavirenz, emtricitabine, tenofovir (Atripla [®]) <i>Abbreviated submission</i>	HIV-1 infection	Pending AMG decision	SMC advice
Insulin glargine (Lantus <i>via</i> SoloStar [®] device) <i>Abbreviated submission</i>	Diabetes mellitus in adults, adolescents, and children over 6 years	Non-formulary	SMC advice SPC link Tayside diabetes handbook
Insulin glulisine (Apidra <i>via</i> SoloStar [®] device) <i>Abbreviated submission</i>	Diabetes mellitus in adults	Non-formulary	SMC advice SPC link Tayside diabetes handbook
Maraviroc (Celsentri [®])	CCR5-tropic HIV-1 infection in combination with other antiretrovirals	Not recommended	SMC advice
Methoxy polyethylene glycol-epoetin beta (Mircera [®])	Anaemia associated with chronic kidney disease (CKD)	HOSPITAL ONLY (renal clinic)	Darbepoetin alfa and epoetin beta are currently the ESAs of choice locally SMC advice SPC link
Nelarabine (Atriance [®])	T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) unresponsive/relapsed after at least two chemotherapy regimens	Pending OHMMG decision	SMC advice
Paliperidone prolonged-release tablets (Invega [®])	Schizophrenia	Not recommended	SMC advice
Retapamulin (Altargo [®]) <i>Non-submission</i>	Short-term treatment of Impetigo and infected small lacerations, abrasions, or sutured wounds	Not recommended	SMC advice
Vildagliptin (Galvus [®])	Type 2 diabetes mellitus as dual therapy in combination with metformin	Non-formulary	Alternative DPP-4 inhibitor to sitagliptin NB SMC has not evaluated vildagliptin in combination with sulphonylureas or glitazones SMC advice SPC link Tayside diabetes handbook

[Click here](#) for Apr 08 SMC briefing note

TAPG Update

	TAPG section	Drug(s)/topic	Changes
2.4	Beta-blockers	Bisoprolol	Range of doses expanded for hypertension and angina.
2.9	Antiplatelets	Antiplatelet drugs	Link to SIGN guidelines No.93 and 97 inserted. Aspirin dose information expanded.
2.12	Lipid-regulating drugs	Statins	Link to SIGN guideline No.93 and 97 inserted. Statement on secondary prevention removed. Information on drug interactions expanded.
2	Cardiovascular guidance notes	Management of stable angina	Bisoprolol now local beta-blocker of choice for stable angina instead of atenolol.
9.4	Oral nutrition	Adult oral nutrition support	Addition of information on adult oral nutrition support supplement drinks and range of products that are preferred within NHS Tayside.
13.4	Topical corticosteroids	Clobetasol propionate 0.05% (Dermovate®) cream, ointment	Removal from VISION TADF (but not Prescribing Guide) to prevent selection of clobetasol propionate (very potent) where prescription of clobetasone butyrate 0.05% (Eumovate®) cream, ointment (moderately potent) is intended.

Switch to Levobupivacaine

NHS Tayside Drug and Therapeutics Committee has agreed to support a change in local anaesthetic agent from bupivacaine to levobupivacaine. The change is planned to be rolled out throughout NHS Tayside, in March and April 2008. The exception to this change is hyperbaric bupivacaine (heavy Marcain®), which will continue to be available. Further information is available within the [Tayside Prescriber Issue 96](#) and [96a](#), March 2008.

Forthcoming SMC Advice

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access to the NHS Tayside Drug and Therapeutics Committee website (www.nhstaysideadtc.scot.nhs.uk).